InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,473.23
(
0.77%
)
US TECH 100
19,409.60
(
1.26%
)
Dow Jones
38,778.10
(
0.49%
)
Brent Oil
83.60
(
-0.36%
)
Bitcoin
65,681.09
(
-1.21%
)
Post# of 252233
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

mcbio

Send PM Follow Ignore
Followers 69
Posts 6152
Boards Moderated 0
Alias Born 11/26/2008

mcbio

Re: genisi post# 150410

Thursday, 04/25/2013 6:43:58 PM

Thursday, April 25, 2013 6:43:58 PM

Post# of 252233
RCPT - MS play going public

http://www.receptos.com/pdfs/Receptos_S-1_filing_pressrelease.pdf

Seems that there's a consensus regarding BG-12 becoming the biggest drug in MS in time. Aubagio doesn't look like a great choice considering its limited efficacy and tox and certainly not a 1st line drug. Alemtuzumab's safety issues will very much limit its use.
No mention of Gilenya just next gen S1P1 compounds?

Curious how hot of an MS target S1P1 is right now. Also, you referenced next gen S1P1 drugs. What are the first gen S1P1 drugs and who are the other competitors in the next gen space besides RCPT?
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up